amino acid substitution is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
Analytical confirmation of identity relies on mass spectrometry, most often coupled to liquid chromatography. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and provides a purity estimate based on peak area. Electrospray ionization mass spectrometry then confirms the expected molecular mass, while tandem mass spectrometry can map the fragment sequence. For research-grade material, these two techniques together form the standard minimum. Purity figures reported by vendors are frequently not traceable to an independent laboratory.
In April 2024 doctors in Rafah performed a similar emergency c-section after an IDF bombardment targeted a housing block in Rafah, the baby survived in critical condition before dying after 5 days. Her mother, father and 3-year-old sister had all been killed in the bombing. In July 2024, yet another baby was delivered by surgeons after the mother was killed by an airstrike. The Women's Centre for Legal Aid and Counselling reported women were suffering from birth complications and a lack of both postpartum care and newborn vaccines. The United Nations Population Fund stated that newborn babies were dying because mothers were unable to access prenatal or postnatal care. According to a UNICEF State of Palestine Humanitarian Situation report, from early March 2024 at least 5,500 pregnant women do not have access to pre or post natal check ups due to the continued airstrike and lack of safe shelter. Doctors at the Al-Helal Al Emirati Hospital reported "chaos and suffering" due to the large influx of displaced people arriving to deliver their babies.
== Research == Beyond acute promyelocytic leukemia (APL), research is exploring arsenic trioxide’s antitumor effects in solid tumors such as glioma, where it induces cancer cell death by regulating apoptosis and autophagy, promoting oxidative stress within tumor cells, and inhibiting tumor stem cells.
MAP kinases (MAPKs) are a family of serine/threonine kinases that respond to a variety of extracellular growth signals. For example, growth hormone, epidermal growth factor, platelet-derived growth factor, and insulin are all considered mitogenic stimuli that can engage the MAPK pathway. Activation of this pathway at the level of the receptor initiates a signaling cascade whereby the Ras GTPase exchanges GDP for GTP. Next, Ras activates Raf kinase (also known as MAPKKK), which activates MEK (MAPKK). MEK activates MAPK (also known as ERK), which can go on to regulate transcription and translation. Whereas RAF and MAPK are both serine/threonine kinases, MAPKK is a tyrosine/threonine kinase.
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC or EDCI) is a water-soluble carbodiimide usually handled as the hydrochloride, which is a white solid. It is typically employed in the 4.0-6.0 pH range. It is generally used as a carboxyl activating agent for the coupling of primary amines to yield amide bonds. While other carbodiimides like dicyclohexylcarbodiimide (DCC) or diisopropylcarbodiimide (DIC) are also employed for this purpose, EDC has the advantage that the urea byproduct formed (often challenging to remove in the case of DCC or DIC) can be washed away from the amide product using dilute acid. Additionally, EDC can also be used to activate phosphate groups in order to form phosphomonoesters and phosphodiesters. Common uses for this carbodiimide include peptide synthesis, protein crosslinking to nucleic acids, but also in the preparation of immunoconjugates. EDC is often used in combination with N-hydroxysuccinimide (NHS) for the immobilisation of large biomolecules. Recent work has also used EDC to assess the structure state of uracil nucleobases in RNA.
Sources: en.wikipedia.org
== Applications == The largest use of metallic calcium is in steelmaking, due to its strong chemical affinity for chalcogens oxygen and sulfur. Its oxides and sulfides, once formed, give liquid lime aluminate and sulfide inclusions in steel which float out; on treatment, these inclusions disperse throughout the steel and become small and spherical, improving castability, cleanliness and general mechanical properties. Calcium is also used in maintenance-free automotive batteries, in which the use of 0.1% calcium–lead alloys instead of the usual antimony–lead alloys leads to lower water loss and lower self-discharging. Due to the risk of expansion and cracking, aluminium is sometimes also incorporated into these alloys. These lead–calcium alloys are also used in casting, replacing lead–antimony alloys. Calcium is also used to strengthen aluminium alloys used for bearings, for the control of graphitic carbon in cast iron, and to remove bismuth impurities from lead. Calcium metal is found in some drain cleaners, where it functions to generate heat and calcium hydroxide that saponifies the fats and liquefies the proteins (for example, those in hair) that block drains. Besides metallurgy, the reactivity of calcium is exploited to remove nitrogen from high-purity argon gas and as a getter for oxygen and nitrogen. It is also used as a reducing agent in the production of chromium, zirconium, thorium, vanadium and uranium. It can also be used to store hydrogen gas, as it reacts with hydrogen to form solid calcium hydride, from which the hydrogen can easily be re-extracted.
== Mechanisms of hepatotoxicity == Since the withdrawal in 2000, mechanisms of troglitazone hepatotoxicity have been extensively studied using a variety of in vivo, in vitro, and computational methods. These studies have suggested that hepatotoxicity of troglitazone results from a combination of metabolic and nonmetabolic factors. The nonmetabolic toxicity is a complex function of drug-protein interactions in the liver and biliary system. Initially, the metabolic toxicity was largely associated with reactive metabolite formation from the thiazolidinedione and chromane rings of troglitazone. Moreover, the formation of quinone and o-quinone methide reactive metabolites were proposed to be formed by metabolic oxidation of the hydroxy group (OH group) of the chromane ring. Detailed quantum chemical analysis of the metabolic pathways for troglitazone has shown that quinone reactive metabolite is generated by oxidation of the OH group, but o-quinone methide reactive metabolite is formed by the oxidation of the methyl groups (CH3 groups) ortho to the OH group of the chromane ring. This understanding has been recently used in the design of novel troglitazone derivatives with antiproliferative activity in breast cancer cell lines.
He commented on the blame for the war, "We might claim that Georgia initiated the war … but it appears at first impression more like a situation when somebody spits in your face twenty days on and finally you react by slapping that person back. Suddenly, the provocateur blames you for the overreaction and says, ‘I have only spit on you but I never hit you…." He further stated, "Russia was the first to breach the 1994 agreement that was negotiated. South Ossetia did not have right to keep heavy artillery on its territory under the terms of this agreement." In October 2008, Russian military expert Vladislav Shurygin wrote that Russia won the war because "the troops and headquarters were preparing for this war" since Spring 2008 when the General Staff began to plan an "operation to force Georgia to peace" and "these tasks were worked out in the spring and summer exercises of the North Caucasus Military District". He continued, "We won because at the staff offices of all levels, there were developed detailed plans in case of the outbreak of this war. [...] We won because in the chaos of muddle and confusion there were those who took responsibility. Who, in the absence of intelligible and clear instructions from Moscow, decided to begin to act according to the plans that were worked out." Shurygin concluded that "had we missed another 2-3 hours, Tskhinvali would have fallen, Georgians would cut off the Transcaucasian Highway".
Chapter 1: Continuous Population Models for Single Species Chapter 2: Discrete Population Models for a Single Species Chapter 3: Models for Interacting Populations Chapter 4: Temperature-Dependent Sex Determination (TSD) Chapter 5: Modelling the Dynamics of Marital Interaction: Divorce Prediction and Marriage Repair Chapter 6: Reaction Kinetics Chapter 7: Biological Oscillators and Switches Chapter 8: BZ Oscillating Reactions Chapter 9: Perturbed and Coupled Oscillators and Black Holes Chapter 10: Dynamics of Infectious Diseases Chapter 11: Reaction Diffusion, Chemotaxis, and Nonlocal Mechanisms Chapter 12: Oscillator-Generated Wave Phenomena Chapter 13: Biological Waves: Single-Species Models Chapter 14: Use and Abuse of Fractals
=== Overlays === Significant structural weaknesses or damaged areas that do not support the textile such as bottom borders of tapestries or hems have different requirements. Borders or edges that are smaller can be wrapped to the back with a sheer overlay fabric to create a binding or facing. Partial or full backing secured with stitching is appropriate in other areas. Protection of exposed floats of the stabilization stitching, may require full-sized secondary linings.
Sources: en.wikipedia.org
The UK government is to examine the potential purchase of The Daily Telegraph by a consortium backed by Sheikh Mansour bin Zayed Al Nahyan. The coldest night in the UK since mid-March is recorded, with temperatures dipping to as low as −9.4 °C (15.1 °F) in Cumbria. Weather warnings remain in place for many regions.
== Journals == Numerous journals are dedicated to the field of proteomics and related areas. Note that journals dealing with proteins are usually more focused on structure and function while proteomics journals are more focused on the large-scale analysis of whole proteomes or at least large sets of proteins. Some relevant proteomics journals are listed below (with their publishers).
== Function == The target of C5 convertase is complement protein C5. C5 is a two-chain (α, β) plasma glycoprotein (Mr = 196,000). C5 and C3 have similar structure. However, C5 does not appear to contain the internal thiol ester group reported for C3 and C4. C5 has relatively few disulfide bonds. There are three disulfide bonds in C5a, the α-chain has 15 half-Cystines, and the β-chain has only 6 half-Cystines. This comparatively low level of stabilizing disulfide bridges may provide a partial explanation for the irreversible conformational change imparted on C5 after cleavage to C5a and C5b. In addition, the relatively low number of disulfide bonds could account for instability of C5 when exposed to chaotropic agents such as potassium thiocyanate. Electron micrographs of negatively stained C5 indicate that the protein is irregular in shape and contains several lobes. First of all, C5 has to bind to C3b fragment. The capacity to bind C3b is a stable feature of component C5, as C5b also has this binding capacity. The C5 convertase selectively cleaves an Arginyl-Leucine peptide bond at position 74-75 in the α-chain (Mr = 116,000) of C5. Research has shown that during the classical pathway of the complement system, an inactive A6 allotype of c4 completely stalls the molecules' ability to act as a c5 binding subunit1. This defect in C4A6 activity happens during the C5 binding step to the 4b and c3b complex. α´-chain (Mr, = 105,000) and the activation peptide, C5a, is formed, while β-chain (Mr = 80,000) remains unchanged.
octanol-water partition coefficient log P not greater than 3 molecular mass less than 300 daltons not more than 3 hydrogen bond donors not more than 3 hydrogen bond acceptors not more than 3 rotatable bonds
The first pass effect (FPE), also known as first-pass metabolism (FPM) or presystemic metabolism, is a phenomenon of drug metabolism at a specific location in the body which leads to a reduction in the concentration of the active drug before it reaches the site of action or systemic circulation. The effect is most associated with orally administered medications, but some drugs still undergo first-pass metabolism even when delivered via an alternate route (e.g., IV, IM, etc.). During this metabolism, drug is lost during the process of absorption which is generally related to the liver and gut wall. The liver is the major site of first pass effect; however, it can also occur in the lungs, vasculature or other metabolically active tissues in the body. Notable drugs that experience a significant first pass effect are buprenorphine, chlorpromazine, cimetidine, diazepam, ethanol (drinking alcohol), imipramine, insulin, lidocaine, midazolam, morphine, pethidine, propranolol, and tetrahydrocannabinol (THC). First-pass metabolism is not to be confused with phase I metabolism, which is a separate process.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.